Skip to main content

Table 16 (abstract P224). Measure of disease activity of the Abirisk patients entered into the Pharmachild registry. Observed data are presented as median (1st-3rd quartile).

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two

 

Baseline

N = 116

Three Months

N = 69

Six Months

N = 41

p-value

JADAS27

11.5 (6.5-16)

2 (0.5-5)

1 (0-8)

<.0001

ESR mm/h

19 (9-37)

7.5 (5-15)

7 (5-16)

<.0001

CRP standardized

9.1 (2-37.5)

2 (1-7.1)

2 (2-10)

0.0002

Nr of active joints

3 (1-6)

0 (0-1)

0 (0-0.5)

<.0001

Nr of LOM

2 (1-6)

0 (0-2)

0 (0-1.5)

<.0001

MDgloVAS

4 (3-6)

0.5 (0-1.5)

0 (0-1.75)

<.0001

VAS pain

3 (1-5)

0.25 (0-1.5)

0 (0-1.5)

<.0001

VAS well-being

3 (1-5)

0 (0-1.5)

0.5 (0-2.5)

<.0001